Research I 7 March 2025 Phase 2 extension close to completion! In this phase, we updated details on the geographical distribution of clinical trials, the use of Patient-Reported Outcome Measures (PROMs), and trends in publishing Patient-Reported Outcomes (PROs). These findings enhance our understanding of clinical trial accessibility and highlight the importance of

Research I 7 March 2025 Advancing Research & Patient Advocacy with a Novel Methodology To generate knowledge, we had to create our own tools, and we hope they are useful for advocacy in other areas too! In collaboration with Syreon, we are proud to be pioneers in developing a novel methodology for

Research I 11 June 2023 Research questions of phase 2 established Where are we at? Research questions have been drafted by the steering committee and have been reviewed and entire oncology and hematological community ensuring that the data outcomes are suited to their needs and answer questions they have around the three main

Research I 11 June 2023 Phase 2 kick off Phase 1 completing and now moving to Phase 2 - analysis nd of phase 1 resulted in the collection of all interventional studies (phase 2,3 or 4) in each disease area. Obtaining the data from either the clinical trial registry, ClinialTrials.gov or EU Clinical

Research I 25 May 2023 EuroACT Phase 1 nears completion Where are we at? The end of Phase 1 Task 1 has resulted in 1262 Patient Related Outcomes (PROs) identified in the targeted literature review across all disease areas. The list of PROs is currently being reviewed by patient organisations in each

Research I 08 Feb 2023 EuroACT Phase 1 meets halfway point The second steering committee meeting concerning the first task within Phase 1, was held on the 1st of February. The aim of task 1 was to identify the most relevant peer-reviewed articles on PROM use practices in the field of oncology